In re Xarelto (Rivaroxaban) Products Liability Litigation

314 F.R.D. 397, 2016 WL 1393429
District Court, E.D. Louisiana·Decided April 8, 2016·No. MDL NO. 2592·Published·Cited by 2 cases

Opinion

[399]*399SECTION L

ORDER & REASONS

ELDON E. FALLON, UNITED STATES DISTRICT JUDGE

Before the Court are the parties’ briefs concerning Defendants’ Motion for Entry of a Protective Order Regarding Attorney Work Product.1 Exs., 1, 2. Having reviewed the parties’ letter briefs, the applicable law, and hearing oral argument the Court now issues this Order & Reasons.

I. BACKGROUND

This matter arises from damages Plaintiffs claim to have suffered from the manufacture, sale, distribution, and/or use of the medication known as Xarelto, an anti-coagulant used for a variety of blood-thinning medical purposes. The Plaintiffs have filed suits in federal courts throughout the nation against Defendants, Bayer Corporation, Bayer Healthcare LLC, Bayer Healthcare Pharmaceuticals Inc., Bayer Healthcare AG, Bayer Pharma AG, and Bayer AG (collectively, Bayer), Janssen Pharmaceuticals, Inc., Janssen Research & Development, LLC, Janssen Ortho LLC, and Johnson & Johnson (collectively, Janssen). The Plaintiffs allege that they or their family members suffered severe bleeding and other injuries due to Xarelto’s allegedly inadequate warning label, among other things, as well as Xarelto’s purported lack of reliance on regular blood monitoring.

The Judicial Panel on Multidistrict Litigation determined that the Plaintiffs’ claims involved common questions of fact and that centralization under 28 U.S.C. § 1407 would serve the convenience of the parties and witnesses and promote the just and efficient conduct of the litigation. Therefore, on December 12, 2014, the Judicial Panel on Multidistrict Litigation consolidated the Plaintiffs’ Xarelto claims into a single multidistrict proceeding (“MDL 2592”). MDL 2592 was assigned to Judge Eldon E. Fallon of the United States District Court for the Eastern District of Louisiana to coordinate discovery and other pretrial matters in the pending cases. Subsequent Xarelto cases filed in federal court have been transferred to this district court to become part of MDL 2592 as “tag along” cases. The Court has appointed committees to represent the parties, and discovery has commenced.

II. THE DEFENDANTS’ MOTION

On March 16, 2016, the parties requested a status conference to discuss an issue pertaining to the discovery of lists of documents which Defense counsel showed to witnesses prior to their depositions. The Court subsequently set telephonic oral argument for March 28, 2016, and ordered the parties to submit letter briefing on the issue by March 23, 2016. R. Doc. 2830. Pursuant to the Court’s Order, the parties timely filed their letter briefs (attached as Exhibits A and B), and participated in oral argument.

In the present motion, Defendants move the Court to issue a pretrial order labeling lists of documents compiled by counsel and shown to a witness prior to a deposition as attorney work product, thereby making the lists immune from discovery.

A. Defendants’ Brief (Ex. A).

Defendants take the position that the production of a list of the documents prepared by defense counsel and used for witness preparation intrudes on confidential opinion work product, because it reveals their opinions as to the significance of various documents and their approach or strategy in handling the matter. Defendants begin by citing case law from other circuits. The Defendants lean heavily on the Third Circuit’s much-cited opinion in Sporck v. Peil, where the circuit court held that the selection and compilation of documents in preparation for pretrial discovery falls within the protected category of opinion work-product. 759 F.2d 312, 316 (3d Cir.1985). Defendants argue that Sporck announced the current majority rule, which they contend is followed by the Fourth and Eighth Circuits. See In re Allen, 106 [400]*400F.3d 582, 608 (4th Cir.1997); Shelton v. Am. Motors Corp., 805 F.2d 1323, 1320 (8th Cir.1986).

Defendants also cite case law from the Fifth Circuit. Defendants first cite Burns v. Exxon Corp., and argue that Burns is controlling. 158 F.3d 336 (1998). In Bums, the district court conducted a Rule 612 in camera review of a list of deposition preparation documents compiled by attorneys, and found that the documents were irrelevant to the issues before the Court. Id. at 342. The district court also found that withholding of the documents was harmless and moot, because the Plaintiffs already had the information in the record. Id at 342-43. On appeal, the Fifth Circuit upheld the district court’s ruling that the list of documents should not be disclosed. Id. at 343.

The Defendants also cite in Hanover Ins. Co. v. Plaquemines Parish Government, 304 F.R.D. 494 (2015). In Hanover, the Parish of Plaquemines claimed that Rule 612 of the Federal Rules of Evidence required the disclosure of all documents shown to the witness prior to the deposition. The District Court disagreed. The Court found that in a case involving over 20,000 documents of written discovery that “selection of documents [to prepare a witness for deposition] necessarily reveals the attorney’s opinions regarding the litigation.” Id. at 500. Defendants close by arguing Bums and Hanover control the present issues, and that the Court should issue a protective order stating the same.

B. Plaintiffs’ Brief (Ex. B)

The PSC argues in opposition that a list of documents used by the witness in preparation for a deposition is not privileged and should be discoverable. Further, they suggest that under Rule 612 of the FRE that they are entitled to know what the witness reviewed so they can effectively cross examine the witness. The PSC cites MDL courts that have compelled the production of lists of documents given to witnesses in preparation for deposition. For instance, the PSC contends that Bayer unsuccessfully raised the present work product objection in In re Trasylol Prod. Liab. Litig., No. 08-MD-1928, 2009 WL 936597, at *3 (S.D.Fla. Apr. 9, 2009). In that case, Judge Middlebrooks of the Southern District of Florida rejected Bayer’s argument, finding that disclosure would not “create[] a real, non-speculative danger of revealing counsel’s thoughts.” Similarly, in the Yaz/Yasmin litigation, Judge Herndon of the Southern District of Illinois held that Plaintiffs should be granted a complete list of the documents and materials reviewed by the witness in preparation for the deposition. In re Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Relevant Prod. Liab. Litig., 2011 WL 2580764, at *3 (S.D.Ill. June 29, 2011). Judge Herndon also employed this procedure in the Pradaxa litigation, finding that “[e]ither party should be allowed to know what documents a witness reviewed prior to a deposition for purposes of efficacy. Neither side will be permitted to ask which, if any, of the documents reviewed were selected by counsel.” In re Pradaxa (Dabigatran Etexilate) Prod. Liab. Litig., 2013 WL 1776433, at *3 (S.D.Ill. Apr.

Free access — add to your briefcase to read the full text and ask questions with AI

In re Xarelto (Rivaroxaban) Products Liability Litigation, 314 F.R.D. 397, 2016 WL 1393429 (E.D. La. 2016).

314 F.R.D. 397 (In re Xarelto (Rivaroxaban) Products Liability Litigation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related